Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant

Table 2 Multivariable Assessments for progression free survival (PFS) and overall survival (OS)

Parameter	Hazard Ratio (95% CI)	p-value
PFS
Double or Triple Hit / Double Expressor status^a
Negative	ref
Positive	5.8 (1.2–23.3)	0.03
Response prior to ASCT		0.03
CR	Ref
PR	3.9 (1.2–13.3)
SD	18.0 (1.3–178.3)
Number of treatment lines prior to ASCT	0.8 (0.4–1.6)	0.62
sIPI
0/1	Ref
2/3	0.7 (0.2–2.6)	0.63
Conditioning Regimen
BEAM ± rituximab	Ref
GemBuMel-based	0.5 (0.1–1.9)	0.31
OS
Response prior to ASCT		< 0.0001
CR	ref
PR	4.2 (2.2–8.7)
SD	6.5 (1.9–18.5)
PD	4.7 (0.9–17.2)
Lines of treatment prior to ASCT	1.1 (0.8–1.5)	0.45
Conditioning Regimen
BEAM ± rituximab	ref
GemBuMel-based	1.0 (0.5–1.8)	0.93

Abbreviations: DH/DE double hit/double expressor, ASCT autologous hematopoietic stem cell transplantation, CR complete remission, PR partial remission, SD stable disease, PD progressive disease, sIPI secondary internation prognostic index, BEAM BCNU, etoposide, cytarabine and melphalan, GemBuMel gemcitabine, busulfan and melphalan
^aConsidered positive if either of the following positive: double hit / triple hit / double expressor. Calculated for patients with DLBCL histology only

ISSN: 1471-2407